Rejected at 1:23 a.m. Feb, 14, 2026 ] by Ahmed7
Author: lhouyang
Related Note: 1488768088581
Rationale for change

Dec 2025: andexanet alfa has been pulled from US market
Source: Society Guidelines - https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/update-safety-andexxa

Rejection reason

accepted another suggestion, thank you!

Extra Extra
Text
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::#UWorld::Step::15390 #AK_Step1_v12::#NinjaNerd::09_Hematology::02_Pathology::15_Antiplatelets,_Anticoagulants,_and_Thrombolytics #AK_Step3_v12::#OME::Intern_Content::Common_Medical_Problems::AFib #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::05_Pharm::04_Direct_coagulation_factor_inhibitors::*Direct_Factor_Xa_Inhibitors #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#B&B::12_Hematology::01_Hemostasis::07_Anticoagulant_Drugs #AK_Step1_v12::#SketchyPharm::03_Blood_&_Inflammation::01_Anticoagulants_&_Thrombolytics::01_Heparin,_LMWH,_fondaparinux,_direct_thrombin_inhibitors,_Xa_inhibitors #AK_Step1_v12::#UWorld::COMLEX::26286 #AK_Step1_v12::#NinjaNerd::04_Pharmacology::01_Basics::03_Antiplatelet,_Anticoagulant,_Thrombolytic_Agents #AK_Step1_v12::#OME::Clinical::Internal_Medicine::Hematology-Oncology::Approach_To_Bleeding #AK_Step1_v12::#Pixorize::03_Pharmacology::11_Heme_Pharm::09_Factor_Xa_Inhibitors_(Apixaban/Rivaroxaban/Edoxaban) #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::02_Coagulation::05_Anticoagulants::Extra #AK_Other::Only_Step_1 #AK_Step1_v12::#NinjaNerd::06_Cardiovascular::04_Pharmacology::04_Direct_Acting_Oral_Anticoagulants_(DOACs)_(MOA,_Indications,_AR,_CI) #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::07_Coagulation_and_Fibrinolysis::10_Anticoagulation